Combination treatment for bladder cancer
View Patent ↗Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and trospium chloride.
1. A method of treating a patient suffering from bladder cancer comprising administering to the patient a therapeutically effective amount of valrubicin, trospium chloride, and a mucin degrading enzyme comprising trypsin or hyaluronidase.
2. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out concomitantly.
3. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out sequentially.
4. The method of claim 1 in which said administration of valrubicin and trospium chloride is carried out parenterally.
5. The method of claim 1 in which said administration of valrubicin is carried out parenterally.
6. The method of claim 1 in which said administration of trospium chloride is carried out enterally.
7. The method of claim 1 in which said administration of valrubicin is carried out parenterally, and said administration of trospium chloride is carried out enterally.
8. The method of claim 1 in which said valrubicin and trospium chloride are co-administered in a combined dosage form comprising about 5 to 100 mg/mL valrubicin, and about 5 to 100 mg/mL trospium chloride.
9. The method of claim 1 further comprising the step of performing a transurethral resection procedure on the patient prior to the administration step.
10. The method of claim 1 in which said administration step is carried out to a patient suffering from superficial bladder cancer.
11. The method of claim 1 in which said administration step is carried out to a patient suffering from carcinoma in situ of urinary bladder.
12. A pharmaceutical composition comprising a therapeutically effective amount of valrubicin or its pharmaceutically acceptable salt, trospium chloride, a mucin degrading enzyme comprising trypsin or hyaluronidase, and optionally a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 which comprising about 5 to 100 mg/mL valrubicin or its pharmaceutically acceptable salt, and about 5 to 100 mg/mL trospium chloride.
14. The method of claim 1 , wherein the mucin degrading enzyme comprises trypsin, animal hyaluronidase, or human recombinant hyaluronidase.
15. The method of claim 1 , wherein the mucin degrading enzyme comprises trypsin.
16. The pharmaceutical composition of claim 12 , wherein the mucin degrading enzyme comprises trypsin, animal hyaluronidase, or human recombinant hyaluronidase.
17. The new pharmaceutical composition of claim 12 , wherein the mucin degrading enzyme comprises trypsin.
18. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier comprises saline.